Securities code: 002107 securities abbreviation: Shandong Wohua Pharmaceutical Co.Ltd(002107) Announcement No.: 2022-012 Shandong Wohua Pharmaceutical Co.Ltd(002107)
Announcement on holding subsidiaries applying for comprehensive credit line from banks
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
Shandong Wohua Pharmaceutical Co.Ltd(002107) (hereinafter referred to as the company) held the 17th meeting of the sixth board of directors on January 19, 2022, and deliberated and adopted the proposal on holding subsidiaries applying for comprehensive credit line from banks. The specific contents are hereby announced as follows:
In order to cope with the current severe economic and industrial situation, turn challenges into opportunities, and meet the needs of rapid growth in the future according to the current business situation, The holding subsidiary Liaoning wohua Kangchen Pharmaceutical Co., Ltd. (hereinafter referred to as Liaoning wohua Kangchen) plans to apply for a comprehensive credit line with a total amount of no more than RMB 90 million from a number of cooperative commercial banks (the final credit line shall be subject to the actual credit line approved by each bank). The above total credit line is not equal to the actual financing amount, and the actual financing amount shall be within the credit line, subject to the actual financing amount of relevant banks.
The management of Liaoning wohua Kangchen should abide by the provisions of relevant laws and regulations and strengthen capital supervision. The authorization period of the above bank’s comprehensive credit extension matters shall be within 1 year from the date of deliberation and approval by the board of directors. Within the authorization period, the credit line can be recycled.
It is hereby announced.
Shandong Wohua Pharmaceutical Co.Ltd(002107) board of directors January 19, 2002
